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MARK4 regulates NLRP3 positioning
and inﬂammasome activation through a
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Excessive activation of the NLR family pyrin domain containing 3 (NLRP3) inﬂammasome is
involved in many chronic inﬂammatory diseases, including cardiovascular and Alzheimer’s
disease. Here we show that microtubule-afﬁnity regulating kinase 4 (MARK4) binds to
NLRP3 and drives it to the microtubule-organizing centre, enabling the formation of one large
inﬂammasome speck complex within a single cell. MARK4 knockdown or knockout, or dis-
ruption of MARK4-NLRP3 interaction, impairs NLRP3 spatial arrangement and limits
inﬂammasome activation. Our results demonstrate how an evolutionarily conserved protein
involved in the regulation of microtubule dynamics orchestrates NLRP3 inﬂammasome
activation by controlling its transport to optimal activation sites, and identify a targetable
function for MARK4 in the control of innate immunity.
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nﬂammasomes are important signalling platforms of the innate
immune system, poised to detect a wide range of molecular
signatures including pathogens and sterile agents. They are
multiprotein complexes with a key component consisting of a
NOD-like receptor (NLR) family member or Pyrin and Hin
domain-containing protein (PYHIN) family member, connected to
caspase-1 mostly through an adaptor protein named apoptosis-
associated Speck-like protein with a caspase-recruitment domain
(ASC, encoded by Pycard). Activation of inﬂammasome pathways
triggers caspase-1-dependent processing of immature interleukin 1b
(pro-IL-1b) into bioactive IL-1b. Activation of NLRP3, an NLR
member of the inﬂammasome family, is linked to the pathogenesis
of various disorders1–3. A better understanding of the regulation
of NLRP3 inﬂammasome activation is therefore required for
the development of effective therapies to combat a range of
inﬂammatory diseases.
Microtubule-dependent sorting is critical for the subcellular
localization of many organelles, vesicles, macromolecules and
pathogens4. Studies indicate that microtubules regulate
intracellular sorting of NLRP3 (refs 5,6), microtubules mediate
assembly of the NLRP3 inﬂammasome6, and microtubule
disruption attenuates NLRP3 inﬂammasome activation5,6. Data
indicate that the centrosomal protein NEK7 is important in the
regulation of NLRP3 activity7–9, but inhibition of tubulin
polymerization does not affect the NLRP3-NEK7 interaction7.
Thus, the molecular mechanisms through which NLRP3 is sorted
in a microtubule-dependent manner, and the functional
consequences of these processes, are not well understood.
The microtubule-afﬁnity regulating kinase 4 (MARK4) protein
was discovered by its ability to phosphorylate microtubule-
associated proteins (MAP) and thereby regulates microtubule
dynamics10. The cellular functions of MARK4 have mostly been
investigated in neurons, but MARK4 has versatile functions that
extend beyond the regulation of microtubule dynamics to a
variety of cellular processes including cell polarity, organelle
positioning, intracellular transport, signal transduction,
ciliogenesis and adipogenesis11–16.
In this study, we identify a functional requirement of MARK4
in the sorting and activation of the NLRP3 inﬂammasome. Our
results show that delivery of NLRP3 through a MARK4-regulated
machinery to the correct position on microtubule-organizing
center (MTOC) is also very important in determining NLRP3
activation. We demonstrate that amongst the various NLR
members of inﬂammasome family, MARK4 selectively interacts
with NLRP3 and promotes its recruitment to mitochondria.
Remarkably, we show that MARK4 drives NLRP3 to MTOC,
thereby allowing NLRP3 positioning to the characteristic speck
structure in a microtubule-dependent manner, and providing an
explanation for the presence of only one inﬂammasome complex
per cell. Furthermore, loss of MARK4 or disruption of the
interaction between NLRP3 and MARK4, alters NLRP3 inﬂam-
masome activation. Finally, we show that loss of MARK4 reduces
neutrophil recruitment upon monosodium urate (MSU)-induced
inﬂammasome activation in vivo. Collectively, these data high-
light a requirement of MARK4 in facilitating microtubule-based
transport of NLRP3, and identify a functional interaction that
regulates NLRP3 positioning and optimal activation output. The
identiﬁcation of MARK4 as a NLRP3 binding partner advances
our understanding of the molecular mechanisms contributing to
inﬂammasome sorting by microtubule-based transport, and
identiﬁes a potential therapeutic target.
Results
Loss of MARK4 alters NLRP3-dependent IL-1b production.
Microtubule-depolymerizing agent colchicine is an effective
medicine to treat the acute phase of gout inﬂammatory disease.
Recent studies indicate that microtubule-driven spatial arrangement
of mitochondria promotes activation of NLRP3 inﬂammasome6.
Moreover, colchicine blocks IL-1b production in response to MSU5.
To conﬁrm the requirement of microtubules in regulating IL-1b
production, we showed that in C57BL/6 mouse bone marrow
derived macrophages (BMDM), microtubule-disrupting drugs
including colchicine, nocodazole, and vinblastine suppressed
IL-1b production in response to the NLRP3 inﬂammasome
stimulus ATP (Supplementary Fig. 1). We therefore addressed in
detail how microtubule-related functions are linked to the
regulation of NLRP3 inﬂammasome activation. MARK4 is
upregulated during permanent focal cerebral ischemia17 and in
brain tissue during Alzheimer’s disease18, indicating a potential
regulatory role in the context of sterile inﬂammation. Mark4 null
mice are protected from diet-induced obesity and insulin
resistance13, a very similar phenotype to Nlrp3 null mice19.
In situ proximity ligation assay (PLA) is suitable for quantitative
studies of protein expression, protein modiﬁcations and close
protein interactions20,21. By using this assay, we found that MARK4
was endogenously expressed in macrophages, including mouse
BMDM (Fig. 1a and Supplementary Fig. 2c) and differentiated
human THP-1 cells (Supplementary Fig. 2a,b). The expression level
of Mark4 was inducible by LPS priming (Fig. 1a and Supplementary
Fig. 2c). Under a wide set of NLRP3 stimuli, including ATP,
nigericin, or sterile crystals, knock down of MARK4 using small
interfering RNAs (siRNA) or short hairpin RNA (shRNA;
Supplementary Fig. 2d) signiﬁcantly reduced IL-1b production
(Fig. 1b,c). We further delineated the speciﬁcity of Mark4 by
demonstrating that Mark4 knock-out (indicated as Mark4 KO or
Mark4 / ) BMDMs had reduced level of IL-1b production
speciﬁcally after activation by NLRP3 stimuli when compared with
wild-type cells (indicated as WT or Mark4þ /þ ), but not after
incubation with stimuli (for example, ﬂagellin, dA:dT, muramyl
dipeptide or iE-DAP) known to induce other inﬂammasome
pathways (Fig. 1d). Upon NLRP3 activation, IL-1b production by
Mark4 KO cells was not totally ablated as compared with Nlrp3 KO
cells, indicating a regulatory role of MARK4 in optimizing NLRP3
activation, or a partial compensatory/redundant mechanism
occurring in Mark4 / BMDMs. Importantly, IL-1b reduction
in Mark4 / cells was not caused by the following: altered levels
of Nlrp3 (Fig. 1e; Supplementary Fig. 3a,b), pro-caspase-1 or pro-
IL-1b substrates (Supplementary Fig. 3); perturbed macrophage
differentiation (Supplementary Fig. 4); compromised phagocytosis
of crystals (Supplementary Fig. 5); or reduced macrophage viability
(Supplementary Fig. 6d,e). Reduced IL-1b levels in Mark4 /
BMDM cells after activation of NLRP3 were due to reduced
generation of active caspase-1 and active IL-1b (Fig. 1e).
Surprisingly, we did not see any difference in cell death rate
between WT and Mark4 KO cells upon NLRP3 inﬂammasome
activation (Supplementary Fig. 6d,e). Inhibition of inﬂammasome-
dependent caspase-1 activation and IL-1b is not always associated
with reduction of cell death22. In the case of Mark4 deﬁciency, this
could be due to residual caspase-1 cleavage, altered cell death
kinetics, or existence of alternative cell death control in Mark4 KO
cells. In addition, inﬂammasome pathway-independent TNF
production was comparable between wild-type and knock-out
cells under different treatment conditions (Supplementary Fig. 6a).
These results indicate a speciﬁc role of Mark4 in Nlrp3
inﬂammasome activation.
MARK4 is primarily associated with NLRP3 inﬂammasome.
NLRP3 inﬂammasome complex include NLRP3 itself, ASC
adaptor, and caspase-1 (ref. 23). By using PLA to detect protein-
protein interaction in situ, we found that Mark4 (or MARK4) was
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associated with Nlrp3 (or NLRP3) in BMDM (Fig. 2a) and THP-1
cells (Supplementary Fig. 7a). This association was enhanced by
NLRP3 inﬂammasome activation (Fig. 2a; Supplementary
Fig. 7a). We further found that microtubule-disrupting agents
including colchicine and nocodazole signiﬁcantly reduced
the degree of association between Mark4 and Nlrp3 in BMDM
cells (Fig. 2a), indicating a requirement for microtubule integrity
in mediating this interaction. To further delineate the direct
association between MARK4 and components in the inﬂamma-
some complex, we co-overexpressed HA-tagged MARK4
respectively with ﬂagged-tagged NLRP3 or ASC in HEK293T cells
that lack endogenous inﬂammasome proteins24. Clearly, we
found that MARK4 co-immunoprecipitated with NLRP3, but not
ASC (Fig. 2b). We also found a greater level of Nlrp3/MarK4
association compared with Asc/Mark4 association in mouse
macrophages under the same experimental conditions (Fig. 2c;
Supplementary Fig. 8), and Nlrp3 deﬁciency further reduced
Mark4/Asc association to background level (Fig. 2c). As expected,
NLRP3 inﬂammasome activation can instigate enhanced level of
Nlrp3/Asc interaction in wild-type cells (Fig. 2d). However,
this Nlrp3/Asc association was signiﬁcantly reduced in Mark4
deﬁcient cells compared with wild-type cells after Nlrp3
inﬂammasome activation (Fig. 2d), strongly indicating Mark4
was involved in forming NLRP3 complex.
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Figure 1 | Loss of MARK4 affects IL-1b production under NLRP3 inﬂammasome activation. (a) Mark4 expression under unprimed and LPS primed
conditions in mouse bone marrow-derived macrophages (BMDM). Cytoplasm proximity ligation assay (PLA) signal per cell cytoplasm is used for
quantiﬁcation. Mean±s.e.m. for all the cells taken from 5 to 8 different views at 40 magniﬁcation for each group. Experiments have been repeated three
times. Scale bar, 10mm. (b) siRNA of MARK4, NLRP3 or ASC caused reduction of ATP induced IL-1b production in THP-1 cells. (c) shRNA of MARK4
caused reduction of IL-1b induced by NLRP3 stimuli, including monosodium urate (MSU) and cholesterol crystals (CC) in THP-1 cells. Mock represents
macrophages without further stimulation. (d) BMDM derived from Mark4 KO mice exhibited selectivity towards NLRP3 activating stimuli. Mean±s.e.m.,
three to four independent experiments combined (b–d), comparisons of the two different groups were analysed by unpaired t test. NS was considered as
not statistically signiﬁcant. *Po0.05, **Po0.01 and ***Po0.001 were considered as statistically signiﬁcant (a–d). (e) Representative western blots of
caspase-1 (Casp1) and IL-1b in the supernatant (Sup.) in Mark4þ /þ and Mark4 / macrophages activated with indicated stimuli. Cell lysates were used
as controls to indicate equal amount of cells for analysis.
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We were also not able to detect any association between
MARK4 and other inﬂammasomes (NLRP1, NLRC4, or Aim2;
Supplementary Fig. 7b), which is in line with the lack of
any impact of Mark4 deﬁciency on IL-1b production in response
to stimuli targeting those inﬂammasome pathways (Fig. 1d).
Furthermore, mammalian MARK family has 4 members, and
NLRP3 was speciﬁcally and highly-associated with MARK4 but
not with other members of the MARK family (Supplementary
Fig. 7c), supporting a speciﬁc role of MARK4 in this pathway.
Collectively, those data demonstrate a genuine, primary and
speciﬁc interaction between MARK4 and NLRP3.
MARK4 has a conserved structure consisting of four distinct
domains, including a kinase and a catalytic domain25,26. NLRP3 is
composed of a C-terminal leucine-rich repeat domain for sensing
the ligands, a central nucleotide-binding domain for oligomeri-
zation, and an N-terminal effector pyrin domain (PYD)23. The
PYD domain of NLRP3 is important for promoting ASC assembly
by binding to GBP5 (ref. 22), and controls positioning of NLRP3 to
mitochondria by binding to MAVS27. To understand the molecular
mechanism of NLRP3/MARK4 association, we mapped the
interaction between NLRP3 and MARK4 using various trunca-
tions of these two proteins. We found that MARK4 catalytic kinase
a
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Figure 2 | MARK4 interacts with NLRP3 in a microtubule-dependent manner. (a) Upon nigericin stimulation (3 mM for 2 h), microtubule-disrupting drugs
colchicine and nocodazole reduced the interaction between Mark4 and Nlrp3, shown by PLA signals in WT BMDM cells. Mark4 KO and Nlrp3 KO BMDM
cells were employed as controls. (b) MARK4 was associated with NLRP3 in co-immunoprecipitation assay. Whole cell lysates were analysed as indication
of transfection. Western blots are representative of 3 independent experiments. (c) Upon nigericin stimulation, PLA signal of NlrpP3 and Mark4, or Asc and
Mark4 in BMDM cells derived fromWTor Nlrp3 KO. Secondary only was employed as control in this PLA assay. (d) PLA signal of Nlrp3 and Asc in BMDM
cells derived from WTor Nlrp3 KO or Asc KO before or after nigericin stimulation (3 mM for 2 h). Mean±s.e.m. for all the cells taken from 5 to 8 different
views at 40 magniﬁcation for each group (a,b,d). Comparisons of the two different groups were analysed by unpaired t-test. NS was considered as not
statistically signiﬁcant. *Po0.05, ***Po0.001 and ****Po0.0001 were considered as statistically signiﬁcant (a,c,d). Results are representatives of three
independent experiments. Scale bar, 10mm.
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domain and NLRP3 Pyrin-NACHT domains were essential for this
interaction (Fig. 3a–c). We therefore mutated to Glycine (G) amino
acids of this PYD region (L41, R43, V52, and L54) predicted to
bind to MARK4. Interestingly V52G displayed a substantial
reduction of binding afﬁnity to MARK4 (Fig. 3d), suggesting an
essential role of this region of NLRP3 in binding to MARK4.
Furthermore, we demonstrated that puriﬁed recombinant MARK4
protein was able to bind to immobilized recombinant NLRP3
protein (1–219 amino acids (aa)) using GST pull-down assay
(Fig. 3e), indicating a direct binding between these two proteins.
MARK4 is involved in NLRP3 positioning along microtubules.
A role for mitochondria in assembly of NLRP3 inﬂammasome has
been demonstrated6,27,28, but we have very little understanding of
how NLRP3 is mobilized from the cytosol to the mitochondria.
A well-known function of MARK4 Drosophila homologue partitio-
ning defective gene 1 (Par-1) is to position macromolecules like
STAUFEN protein and oskarmRNA to the correct destination in a
microtubule-dependent manner29. However, the mechanism
through which Par-1 delivers such function is still not fully
understood. We directly observed the transport of NLRP3 along
microtubules in living cells. We found that stimuli causing NLRP3
inﬂammasome activation like nigericin, acting as polarizing inputs,
induced dynamic NLRP3 transport along microtubules to meet
mitochondria (Fig. 4a; Supplementary Movie 1). NLRP3 particles
were able to move for a long distance (up to 12.7mm) with a high
speed (up to 577 nm s s), and displayed both uni-directional and
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Figure 3 | Mapping of interacting domains between MARK4 and NLRP3. (a) Western blots of co-immunoprecipitated full-length NLRP3 with truncated
MARK4 (KD: kinase domain; CD: catalytic domain; UBA: Ubiquitin-associated domain), respectively. (b) Western blots of coimmunoprecipitated truncated
NLRP3 (Pyrin Del: pyrin domain deletion; Pyrin only: pyrin domain only; NACHT: Nucleotide-binding oligomerization domain; LRR: Leucine-rich repeat) with full-
length MARK4, or co-immunopreciptated MARK4 with truncated NLRP3, respectively. (c) Schematic diagram showing that MARK4 catalytic kinase domain
and NLRP3 Pyrin &NACHT domain were essential for their interaction. (d) Western blots of co-immunoprecipitated NLRP3 point mutants with MARK4
respectively. Whole cell lysates were analysed as indication of transfection. (e) Puriﬁed recombinant NLRP3 (1-291aa) immobilized on the glutathione
sepharose can pull down puriﬁed recombinant full-length MARK4 directly. Western blots are representatives of three independent experiments.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15986 ARTICLE
NATURE COMMUNICATIONS | 8:15986 |DOI: 10.1038/ncomms15986 | www.nature.com/naturecommunications 5
bi-directional motor-dependent movements (Supplementary
Fig. 9a; Supplementary Movie 2), further supporting a
microtubule-dependent transport of NLRP3. In addition, we
further conﬁrmed that shuttling of NLRP3 protein to the
mitochondria was substantially reduced in MARK4 knock-down
macrophages (Fig. 4b; Supplementary Movie 3; Supplementary
Fig. 10), supporting a direct role for MARK4 in the transport of
NLRP3 from other compartments to mitochondria. Interestingly,
there was no apparent difference of run length and run speed of
mobile NLRP3 particles in MARK4 knock-down cells when
compared with controls (Supplementary Fig. 9b; Supplementary
Movie 2), indicating that the positioning defect was not due to a
delayed transport process in the absence of MARK4. Together, our
results strongly support an evolutionarily conserved role of
MARK4 in microtubule-dependent transport.
MARK4 drives NLRP3 to MTOC upon inﬂammasome activation.
MARKs were originally identiﬁed through their ability to regulate
microtubule stability by phosphorylating and dissociating
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Figure 4 | MARK4 is involved in NLRP3 positioning along microtubules. (a) Upon nigericin stimulation (3 mM), NLRP3 (arrow) was moving along
microtubules (MT) to meet mitochondria (arrowhead) in THP-1 cells stably expressing NLRP3-cherry. Scale bar, 2mm. See also Supplementary Movie 1.
(b) Orthogonal view of NLRP3 with mitochondria in THP-1 cells stably expressing shRNA of MARK4 or scrambled controls. See also Supplementary
Movie 2. (c) Cherry-NLRP3 and GFP-MARK4 were moving together towards MTOC in differentiated THP-1 cells upon nigericin stimulation. Histogram
mean of MARK4-GFP was calculated within the indicated square. Arrowheads indicate MTOC. See also Supplementary Movie 4. (d) Orthogonal view of
NLRP3 with microtubule in THP-1 cells stably expressing NLRP3-Cherry before or after stimulation by nigericin (10mM for 2 h); orthogonal view was
centered around MTOC. See also Supplementary Movie 5. Experiments were repeated at least three times. Scale bar, 10mm (b–d).
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MAPs30. This association has been shown to regulate
microtubule-based transport by removing MAPs that would
otherwise hinder the attachment and/or movement of motors
along microtubules in neuronal cells30. MAPs in RAW264.7
macrophages may be dynamically regulated upon inﬂammatory
activation31. In addition, assembly of the NLRP3 inﬂammasome
is regulated by acetylated a-tubulin6. Here we show that loss of
Mark4 doesn’t affect Maps, acetylated tubulin or total tubulin
levels (Supplementary Fig. 3), mitigating the possibility that
aberrant NLRP3 positioning was caused by these microtubule-
relevant mechanisms. MARK4 co-localizes with microtubules,
and speciﬁcally binds to MTOC10. We found that upon
inﬂammasome activation, MARK4 and NLRP3 moved together
towards MTOC, and MARK4 was accumulating on MTOC with
time (Fig. 4c; Supplementary Movie 4). By highlighting
microtubule structures, we further demonstrated that NLRP3
accumulated around MTOC upon inﬂammasome activation
(Fig. 4d; Supplementary Movie 5).
It is known that inﬂammasome activation can lead to one big
speck structure per cell32,33, but it is not known what this
structure is, and why it is only a single speck complex within a
given cell. Assembly of inﬂammasome in a uniﬁed manner is
suggested to promote proximity-induced cleavage and further
activation32, and MTOC can provide such a platform for efﬁcient
processing of inﬂammasome complex. Here we show that in
macrophages expressing endogenous levels of MARK4 and
NLRP3, MARK4 and NLRP3 co-localized on MTOC (g-tubulin
staining) and formed the classic single speck structure upon
inﬂammasome activation (Fig. 5a). Almost every NLRP3
speck (98%) spotted had clear MARK4 co-localized with it on
the MTOC. In HEK293T cells, overexpressed MARK4 drove
over-expressed NLRP3 onto this speck structure on MTOC
(Fig. 5b and Supplementary Fig. 11). Remarkably, MARK4
knock-down led to a dilated NLRP3 structure of 4.94 mm on
average, when compared with a condensed NLRP3 speck
structure of 2.59 mm on average in MARK4 overexpressed cells
(Fig. 5b).
We further observed the speck structure at higher magniﬁca-
tion, and found that NLRP3 was no longer located at
mitochondria organelle after speck formation, and mitochondria
were detected around the speck (Fig. 5c). Remarkably, MARK4
knock-down prevented NLRP3 from forming stereotypical speck
structure on the MTOC (Fig. 5c,d). It led to a dilated NLRP3 ring
structure, prevented NLRP3 nucleation on MTOC, and disrupted
speck formation in HEK293T cell (Fig. 5c; Supplementary
Movie 6). Disrupted speck formation and microtubule nucleation
were also conﬁrmed when endogenous levels of MAKR4 were
knocked down in THP-1 cells (Fig. 5d). The remarkable
prevention of NLRP3 forming speck on MTOC when MARK4
level is reduced strongly supports a critical role for MARK4 as a
driving force for NLRP3 to localize and nucleate on MTOC.
In addition, ASC is conﬁrmed in the speck structure at the
MTOC (Supplementary Fig. 12a). In the MARK4 knock-known
cells, ASC was also dilated and not at the MTOC (Supplementary
Fig. 12b), suggesting that ASC localization on the MTOC ﬁrst
requires NLRP3 positioning at MTOC. Moreover, we found that
ASC oligomerization was reduced in MARK4 deﬁcient cells
following inﬂammasome activation (Supplementary Fig. 13). The
effect of MARK4 on ASC oligomerization is probably indirect
and may have resulted from altered NLRP3 positioning and
subsequent ineffective speck formation. However, the subsided
co-localization of NLRP3 and ASC in the wrong place (outside of
MTOC) may still be able to constitute a partial activation, shown
by compromised and incomplete IL-1b release in the MARK4
knock-out cells (Fig. 1). In summary, our data identify a
previously unsuspected role for MARK4 in driving NLRP3 in
the formation of one big condensed speck structure in the cell
following its activation, and support an evolutionarily conserved
role of MARK in the organization of microtubules and in
arranging the distribution of their binding partners.
Disruption of MARK4-NLRP3 interaction alters speck formation.
We found that a region present in NLRP3 PYD domain34,35,
displayed high structural similarity with a known structure of
CagA36 (Supplementary Fig. 14a,b), a peptide originally
derived from Helicobacter pylori and subsequently shown to
mimic the substrates of MARK proteins15,18,36,37. According to
the structural alignment between NLRP3 PYD and CagA peptide,
we hypothesized that CagA peptide may be employed as a NLRP3
binding competitor against MARK4 to disrupt MARK4-NLRP3
interaction. A control peptide was designed by mutating the
predicted binding sites to glycine (Supplementary Fig. 14c).
Indeed, incubation with CagA peptide before NLRP3 stimulation
with nigericin abrogated the interaction between NLRP3 and
MARK4 in THP-1 cells (Fig. 6a), conﬁrming our hypothesis.
Moreover, treatment with CagA peptide led to a dose-dependent
reduction of caspase-1 activation and IL-1b production in
WT BMDMs (Fig. 6b; Supplementary Fig. 14d). CagA peptide
did not alter inﬂammasome-induced IL-1b production in Mark4
deﬁcient cells (Fig. 6b), indicating a Mark4-dependent effect of
this peptide. The results strongly support the use of CagA peptide
as a potent and selective inhibitor of NLRP3 inﬂammasome
pathway. Inhibition of Mark4/Nlrp3 interaction, by CagA
treatment or using Mark4 KO, also reduced the interaction
between Nlrp3 and Asc (Fig. 6c), demonstrating an important
role of Mark4/Nlrp3 interaction in the assembly of an optimal
inﬂammasome complex. Moreover, CagA peptide prevented
NLRP3 from forming a speck on MTOC (Fig. 6d). The
overlapping of MTOC with NLRP3 speck structure was
signiﬁcantly reduced by treatment with CagA peptide (Fig. 6d).
Our data collectively highlight an essential role of MARK4 in
generating an optimal level of NLRP3 inﬂammasome activation.
MARK4 promotes NLRP3-dependent responses in vivo. MSU
crystals accumulate in gout disease and trigger NLRP3-dependent
innate immune system activation leading to the release of IL-1b,
which is responsible for the neutrophilic gouty inﬂammation38,39.
To assess the contribution of Mark4 to Nlrp3 activation in vivo,
we used a well-validated Nlrp3-dependent acute sterile inﬂa-
mmatory model in mice, induced by the injection of MSU into the
peritoneal cavity5. As expected, we detected a pronounced inﬂux of
neutrophils (Ly6Ghi Ly6Cþ cells) into the peritoneum of
wild-type Mark4þ /þ mice 6 h after MSU injection (Fig. 7a–c),
which was largely dependent on NLRP3 activation and IL-1b
production (Fig. 7b,c) because it was substantially reduced in
Nlrp3 / mice or after administration of a neutralizing anti-IL-1b
antibody (Fig. 7b,c). Interestingly, IL-1b production and neutrophil
accumulation in peritoneal lavage were markedly reduced after
MSU injection into Mark4 / mice compared with wild-type
littermate controls (Fig. 7b,c), whereas TNF release was comparable
between the 2 groups of mice (Fig. 7d), indicating a substantial and
speciﬁc reduction of the inﬂammatory response. Furthermore, the
effect of Mark4 on neutrophil accumulation was totally dependent
on IL-1b production, as there was no further reduction of
neutrophil recruitment in MarK4 / mice after treatment
with IL-1b neutralizing antibody (Fig. 7b). Mark4 deletion did
not affect the peritoneal inﬂammatory response to thioglycollate,
an inﬂammasome-independent stimulus (Fig. 7b–d). In addition,
Mark4 deletion did not compromise neutrophil migration per se
(Supplementary Fig. 15). Thus, Mark4 was required for Nlrp3-
mediated IL-1b production and inﬂammation in vivo.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15986 ARTICLE
NATURE COMMUNICATIONS | 8:15986 |DOI: 10.1038/ncomms15986 | www.nature.com/naturecommunications 7
Discussion
The importance of microtubules in the response of macrophages to
inﬂammatory stimuli has been suggested in very early studies40, and
recent work has linked microtubule function with inﬂammasome
activity5,6. However, the molecular mechanisms behind this
function remained largely unknown. Here we identify MARK4 as
a speciﬁc immune modulator of NLRP3 inﬂammasome. We have
made several observations that point to MARK4 as a speciﬁc player
in NLRP3 inﬂammasome pathway. First, MARK4 speciﬁcally
regulates NLRP3 inﬂammasome but does not affect several other
inﬂammasome pathways examined, which is rendered possibly by a
unique interaction between NLRP3 and MARK4 proteins.
Secondly, other MARK family members (MARK1, MARK2 and
MARK3) show very limited binding ability to NLRP3, supporting a
distinct role of MARK4 in this pathway. Thirdly, MARK4 regulates
NLRP3 inﬂammasome activation by speciﬁcally targeting a fraction
of NLRP3. This fraction of NLRP3 requires MARK4 for its
shuttling to sites of optimal activation. Therefore, inﬂammasome
activation is signiﬁcantly reduced but not completely abolished in
MARK4 knock-out cells upon both crystalline and noncrystalline
activators, which may preserve a homeostatic inﬂammatory
response. In this regard, it is interesting to note that loss of
MAVS, a mitochondria protein required for assembly of
inﬂammasome complex on this organelle, also results in a partial
repression of inﬂammasome activation in response to non-
crystalline activators, and does not alter NLRP3 inﬂammasome
activation by non-crystalline activators27,41. Thus, it is plausible that
different molecules like MARK4 and MAVS are allocated different
but complementary tasks during the process of inﬂammasome
activation, and that such division of labour may ensure optimal
regulation of NLRP3 positioning and activation in response to
polarizing cues. This hypothesis merits further investigation.
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Figure 5 | MARK4 deﬁciency affects MTOC and speck nucleation. (a) Differentiated THP-1 cells were stimulated with nigericin (10 mM for 1.5 h) or left
untreated (control). Endogeneous levels of NLRP3 and MARK4 were co-stained with g-tubulin. (b,c) HEK293T cells were co-overexpressed with
GFP-MARK4, Cherry-NLRP3 and ASC-Flag (indicated as MARK4 GFP o.e.); or co-overexpressed with MARK4 shRNA (shown by green GFP),
Cherry-NLRP3 and ASC-Flag (indicated as MARK4 shRNA). co-overexpression with MARK4-GFP drove NLRP3 to MTOC, and knock down of MARK4 by
shRNA (indicated by GFP) led to a dilated ring structure of NLRP3. Quantiﬁcation of speck size was shown. Scale bar, 40mm. Mean±s.e.m. for all the cells
taken from ﬁve different views at  20 magniﬁcation for each group. Comparisons of the two different groups were analysed by unpaired t-test.
****Po0.0001 was considered as statistically signiﬁcant (b). Mitochondria distribution was shown after speck formation (c). See also Supplementary
Movie 6. (d) In differentiated THP-1 cells, upon nigericin stimulation (10 mM for 1.5 h), NLRP3 was translocated to MTOC, indicated by g-tubulin. NLRP3
remained in cytoplasm distribution in MARK4 shRNA cell. Experiments were repeated at least three times. Scale bar, 10mm.
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Figure 6 | CagA impairs inﬂammasome activation by disrupting NLRP3-MARK4 interaction. (a) CagA peptide impaired the interaction between NLRP3
and MARK4 upon NLRP3 inﬂammasome activation by nigericin (3 mM for 2 h) in the differentiated THP-1 cells. A control peptide was employed. Scale bar,
10mm. (b) ELISA of IL-1b level in the supernatants of WT BMDM cells following pretreatment of CagA peptide (with indicated concentrations) and nigericin
stimulation (10 mM for 1 h). Mark4 KO cells were used as controls. (c) CagA peptide prevented formation of Nlrp3 and Asc complex under nigericin
stimulation (3 mM for 2 h) in WT BMDMs. Mark4 KO cells were used as controls. Scale bar, 10mm. Mean±s.e.m. for all the cells taken from ﬁve different
views at 40 magniﬁcation for each group (a,c). (d) CagA peptide impaired the formation of NLRP3 speck on MTOC upon NLRP3 inﬂammasome
activation (MSU 250mgml 1 for 6 h) in the differentiated THP-1 cells. Inset was used to display magniﬁcation of the boxed region as examples of MARK4,
NLRP3, and g-tubulin localization. Scale bar, 20mm. Mean±s.e.m., at least three experiments (a–d). Comparisons of the two different groups were
analysed by unpaired t test. NS was considered as not statistically signiﬁcant. *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001 were considered as
statistically signiﬁcant (a–d).
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MARKs and their invertebrate homologue Par-1 are conserved
regulators of the organization of microtubule arrays, and they are
important for the establishment of cell polarity and for fate
determination in polarized structures like Drosophila oocytes
and epithelia15,29,42. There is a network of cross-regulatory and
feedback interactions between MARK (Par-1) protein, other
polarity regulators and the cytoskeleton. Studies show that
distinct microtubule-based transport mechanisms contribute to
the establishment of PAR and its substrates asymmetries in
different cell types30,43,44, and PAR also drives the proper
organization of microtubules42,45. However, we did not know
whether similar mechanisms were employed by MARK4 in
the context of the innate immune response.
Here we demonstrate that inﬂammasome stimuli can act as
polarizing cues to initiate dynamic NLRP3 and MARK4 transport
in macrophages. How MARK4 modulates microtubule organiza-
tion in these contexts remains to be explored. This modulation
might involve control over microtubule stability or distribution of
nucleation sites, and regulation of protein trafﬁcking through
MARK4 ability to interact with components of the cell’s
apparatus. Microtubule acetylation is an important regulator of
NLRP3 activation6. However, we did not detect any alteration of
total or acetylated tubulin in MARK4 deﬁcient cells, suggesting
that MARK4 regulates NLRP3 activity through different mecha-
nisms. Rather, we showed that MARK4 affected microtubule
nucleation and the distribution of its binding partner NLRP3 on
microtubule polarized minus end of MTOC, in agreement with
the developmentally conserved role of MARK4. Binding of
MARK4 to NLRP3 was required for NLRP3 transport to the
mitochondria but also for delivering NLRP3 on MTOC, leading
to the formation of a single inﬂammasome complex per cell
and ensuring optimal activation of the inﬂammasome. Our
study reveals a previously unappreciated mechanism through
which a MARK protein can facilitate the formation of a complex
structure involved in the activation of innate immunity.
Recent data indicate that a centrosomal protein NEK7 is
important in the regulation of NLRP3 activity7–9. Our results
add more to this scenario and show that delivery of NLRP3
through a MARK4-regulated machinery to the correct position
on MTOC (centrosome) is also very important in determining
NLRP3 activation.
Our results show that NLRP3 is very dynamic within the cell
and is transported along microtubules. Why does NLRP3 need to
be transported along this cytoskeleton? Inﬂammasome activation
requires a few components to form one big complex, and also the
protease activity to cleave the pro-form proteins and then deliver
the ﬁnal active output. Hence, inﬂammasome needs platforms
like MTOC for efﬁcient complex assembly and cleavage. Thus,
upon receiving stimuli (polarizing cues) at the cell periphery,
NLRP3 loading on the microtubule plus end track will allow its
fast trafﬁcking along microtubules for its correct delivery to
microtubule minus end at MTOC (centrosome). On the basis of
our data and previous knowledge, we propose that upon
stimulation, on its trafﬁcking route to MTOC, NLRP3 is ﬁrst
transported along the microtubule track to meet mitochondria,
perhaps for its optimal energy loading, then further transported
to the microtubule track minus end MTOC for optimal assembly
and efﬁcient protein cleavage (Supplementary Fig. 16). MARK4
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Figure 7 | Mark4 promotes Nlrp3-dependent responses in vivo. Representative images of neutrophil recruitment by ﬂow cytometry are shown in mice
injected intraperitoneally (i.p.) with MSU (a). Neutrophil count (b), IL-1b (c) and TNF levels (d) in peritoneal exudate of mice (Mark4 / , Mark4þ /þ ,
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affects the transport of NLRP3 to those destinations, rather than
affecting the assembly of the big complex. In addition, we observe
that once NLRP3 reaches the MTOC and assembles into a single
speck structure, it is no longer localized on the mitochondria,
which are now surrounding the MTOC, suggesting that
localization of NLRP3 to the mitochondria is a transient state.
Furthermore, it is still not clear how IL-1b is released upon
NLRP3 activation, and whether IL-1b release relies on micro-
tubule-dependent transport and MARK4 function. Those
hypotheses need to be further investigated in details. However,
targeting MARK4/NLRP3 interaction or loss of MARK4
signiﬁcantly affects NLRP3 inﬂammasome transport, positioning
on MTOC, ASC oligomerization, and levels of caspase-1
and IL-1b in active forms (Figs 1 and 6; Supplementary
Figs 13 and 14), strongly suggesting that interaction between
MARK4 and NLRP3 is required for optimal NLRP3 function.
Taken together, our data unravel novel mechanistic roles of
MARK4 in regulating NLRP3 inﬂammasome activation. Most
current therapeutic strategies aimed at reducing NLRP3-mediated
diseases involve blockade of the end-product IL-1b. Such
strategies entail a number of potential undesirable effects, which
are frequently associated with the suppression of a major cytokine
involved in a wide range of NLRP3-dependent and -independent
(patho) physiological processes. In this regard, our study clearly
highlights an unconventional and more selective strategy for
suppression of excessive NLRP3 inﬂammasome through the
targeting of MARK4/NLRP3 interaction.
Methods
Mice. Mark4 / (ref. 13) and Nlrp3 / (ref. 5) mice were described. All mice
were fully backcrossed to a C57BL/6 background. Dr Aubry Tardivel (University of
Lausanne, Switzerland) provided bone marrow cells from Nlrp3 / mice, and
Prof Clare Bryant (University of Cambridge, UK) and Prof Kate Fitzgerald
(UMASS medical school, USA) provided Nlrp3 / mice. All studies were
approved by Home Ofﬁce, United Kingdom, and were performed under PPL
80/2426.
MSU-induced peritonitis model. Age (8 to 10 weeks) and sex-matched male
Mark4 / mice and their littermate Mark4þ /þ wild-type controls were used for
in vivo experiments. The littermates were obtained by breeding Mark4 /þ
parents. Mouse fed with a chow diet was injected intravenously with 10 mg of
anti-IL-1b antibody (AF-401-NA, R&D). After 30min, mouse was injected
intraperitoneally with 1mg MSU in 0.3ml sterile PBS. Six hours after MSU
injection, animals were killed by CO2 asphyxiation and peritoneal exudates were
collected by lavage and analysed.
Reagents. ATP, Ultrapure LPS, colchicine, nocodazole, MDP, Phorbol
12-myristate 13-acetate (PMA), and doxycycline were obtained from Sigma. Imject
Alum was obtained from Thermo. Nigericin, ﬂagellin, poly (dA:dT) and vinblastine
were obtained from Enzo. iE-DAP was obtained from Invivogen. MSU crystals and
cholesterol crystals were made as described46,47: cholesterol (Sigma) dissolved in
95% ethanol (12.5 g l 1) was heated to 60 C, ﬁltered through ﬁlter paper and left
at room temperature to allow crystallization; 8 g of uric acid (Sigma) was dissolved
in 1,600ml of boiling water containing 49ml NaOH, and then PH was adjusted
to 7.2, and crystals were formed by gradual cooling down. DOTAP (Roche),
TransIT/LT1 (MirusBio), and TransIT/TKO (MirusBio) were used as transfection
reagents. Mitotracker Red, Mitotracker Deep Red FM, TubulinTracker Green,
Hoechst 33342, DAPI were obtained from Invitrogen. CytoTox 96 non-radioactive
cytotoxicity assay (Promega) was used to measure lactate dehydrogenase (LDH) as
an indication of cell viability following manufacturer’s instruction.
Plasmids and molecular biology. Human NLRP3 cDNA clone was purchased
from Applied Biological Materials. Full-length and truncated human NLRP3
(94–979; 1–220; 1–389; 1–574; 575–979) were subcloned into pCMV-3Tag-1. Point
mutations (L41G; R43G; V52G; L54G) were created by site-directed mutagenesis.
Human NLRP1, mouse NLRC4, and human AIM2 cloned into pCMV-3Tag-1
(Flag tag) were obtained from Dr John MacMicking (University of Yale, USA).
Human ASC subcloned into pCA7-Flag was obtained from Dr Takechi Ichinohe
and Dr Yusuke Yanagi (Kyushu University, Japan). Full-length NLRP3 was
subcloned into pmCherry vector (vector backbone was obtained from Dr Christien
Merriﬁeld, CNRS, France). Full-length human MARK1, MARK2, MARK3,
MARK4, and truncations of MARK4 cloned into pCMV-HA vector, and
GFP-MARK4 cloned into pEGFP-C2 vector were obtained from MRC-PPU
(the University of Dundee, UK). Human MARK4 shRNA, scrambled shRNA
control, and lentivirus packaging plasmids were purchased (Origene).
Tet-O-FUW-EGFP (Addgene) was modiﬁed to subclone GFP-MARK4 or
Cherry-NLRP3 into Tet-O-FUW backbone. FUW-M2rtTA (Addgene) was
used to co-express the reverse tetracycline tansactivator. NLRP3 (1-219 aa) was
subcloned into pGEX-4T-3 vector to express GST fusion protein.
Antibodies. Antibodies against NLRP3 (Adipogen, Cryo2) (Sigma, HPA012878),
IL-1b (R&D systems, AF-401-NA), caspase-1 (Santa Cruz, SC-154), MAP1 (Sigma,
HM-1), NEK7 (Abcam, ab133514), MAP4 (BD, 611026), a-tubulin (MBL, PM054),
acetylated tubulin (Santa Cruz, SC-23950), g-tubulin (Sigma, T5326), Tom20
(Santa Cruz, FL-145, SC-11451), ERK2 (Santa Cruz, C-14), HA tag (Santa Cruz,
y-11), Flag tag (Sigma, F1804) were used for western blots. Antibodies against
MARK4 (Cell Signaling, 4834) (Abcam, ab124267) (house-made by MRC-PPU, the
University of Dundee, UK), NLRP3 (Sigma, HPA012878; Abcam, ab4207),
ASC (Enzo, ADI-905-173) (Santa Cruz, SC-33958) were used for in situ
proximity-ligation assay. Antibodies against markers CD11b (BIOLEGEND,
101217, 1 in 800 dilution), F4/80 (ebiosciences, 25-4801-82, 1 in 200 dilution),
Ly6G (BD, 551461, 1 in 400 dilution), and Ly6C (AbD SeroTec, mca771a647,
1 in 400 dilution) were used for ﬂow cytometry. See Supplementary Fig. 15d for
gating strategy for peritoneal exudates.
Cell culture. Bone marrow cells were dissected from femur and tibia from 6-week
old male mice. Bone marrow cells were differentiated into macrophages as
previously described48 by using 25% conditional medium from L929 cells (ATCC)
enriched with macrophage colony-stimulating factor (M-CSF) for 7 to 10 days. The
differentiation of BMDM was conﬁrmed by ﬂow cytometry with markers CD11b
and F4/80. THP-1 cells (ATCC) were cultured in RPMI-1640 (Invitrogen)
supplemented with 10% FBS and antibiotics. THP-1 cells were differentiated into
macrophages by adding 200 nM of PMA for 48 to 72 h. HEK293T cells were
cultured in DMEM (Sigma) supplemented with 10% FBS, 2mM of L-Glutamine,
1mM of sodium pyruvate and antibiotics. Cells were cultured at 37 C, 5% CO2 in
the humidiﬁed incubator.
Treatments. Inﬂammasome activation was induced by the following treatments as
indicated: 5mM of ATP for 30min; 3 mM of nigericin for 2 h; 10mM of nigericin
for 1 h; 250 mgml 1 of MSU for 3 h; 250 mgml 1 of cholesterol crystals for 3 h;
250 mgml 1 of Alum crystals for 3 h; 1 mgml 1 of ﬂagellin for 2 h; 2 mgml 1 of
poly (dA:dT) for 2 h; 10mgml 1 of MDP for 18 h; 10mgml 1 of iE-DAP for 18 h.
Before inﬂammasome activation, BMDM cells were pretreated with the following
reagents: 10mM of colchicine for 1 h; 10mM of nocodazole for 1 h; 10 mM of
vinblastine for 1 h. BMDM were primed with LPS 100 ngml 1 for 6 h before
inﬂammasome activation.
Lentivirus transduction. Lentivirus expression plasmids (Origene) were packaged
and produced by transient transfection of packaging HEK293T cells (ATCC)
following manufacturer’s instruction (Origene). THP1 cells or BMDM were
transduced with packaged lentivirus following manufacturer’s instruction
(Origene). Stably transduced THP-1 cells were selected by GFP or Cherry
ﬂuorescence using ﬂow sorting. Tet-on system was used as described49 to
induce Cherry-NLRP3 or GFP-MARK4 in THP-1 cells or BMDM by adding
doxycycline (2 mgml 1).
Transfection. On-target siRNAs were obtained from Dharmacon technologies
(Thermo), and siRNA of non-targeting pool was used as a negative control.
siRNA were transfected using TransIT TKO (Mirus Bio) as per manufactuer’s
instructions. HEK293T cells were transfected with plasmids using TransIT/LT1
following manufacturer’s instruction, and the transfection efﬁciency was
achieved more than 92%. One hour before inﬂammasome activation, cells were
transfected with CagA peptide (GFPLKRHDGVDDLSKVG) and control peptide
(GFPGKGHDGGDDGSKVG) (synthesized by Thermo Scientiﬁc or Caslo
Denmark) at the indicated concentrations following manufacturer’s instruction
of DOTAP reagent. Flagellin and double-stranded DNA were transfected with
DOTAP reagent.
Live cell labelling and imaging. HEK293T cells or THP-1 cells were grown on the
eight-well chamber (Nunc). Cells were labeled with Mitotracker Red, Mitotracker
Deep Red FM, TubulinTracker Green, and Hoechst following manufacturer’s
instruction. Nucleus was revealed in blue in all the images. Live cell imaging was
performed at 37 C using confocal microscopes: Carl Zeiss LSM 700, Opterra
(Bruker) or Andor Spinning Disk (Oxford Instruments). Z-sections were taken to
reconstitute 3D structure. Images were processed and analysed using ImageJ.
Analysis of NLRP3 motility. The intracellular translocation of ﬂuorescent NLRP3
particles was analysed using Image processing program, ImageJ (NIH). The
particles movements were tracked by generating time-space plot or kymograph.
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First, the region of interest (ROI) in the cell was determined for each individual
particle/ﬂuorescent spot, and line ROI is drawn across the length of the movement
that is manually monitored. Kymograph was generated that represents position of
the ﬂuorescent spot through the 100 frames of images. On kymograph, x axis
represents the distance and y axis represents the time. The particle movement is
seen as the change in position of high intensity spot from previous frames; the
immobile particle appears as a single high intensity line parallel to Y axis. Examples
of kymographs illustrating unidirectional, bidirectional movements along the
region of interest were presented. The run lengths and velocities were then
calculated manually from the position of spots on kymographs. Run length
was determined as a distance ﬂuorescent particle travelled before stalling or
reversing/changing the direction of movement. Velocity was calculated as
displacement per interval time. N¼ 111 (from 3 cells) for Control shRNA and
N¼ 136 (from 4 cells) particles tracks for MARK4 shRNA were analysed.
In situ proximity-ligation assay. In situ proximity ligation assay (in situ PLA) is
suitable for quantitative studies of protein expressions, and to characterize
modiﬁcations and interactions of proteins20,21. The cells were cultured on
eight-well chamber slide (Nunc). PLA assay was performed according to
manufacturer’s instruction (Olink). Living cells treated with mitotracker Red
CMXRos were ﬁxed by 4% PFA, and then subject to PLA assay. Nucleus was
revealed in blue in the images. PLA signal (indicated by symbol ‘X’) per cytoplasm
of a cell were acquired using Duolink analysis software (Olink). Mitochondria
overplapped with PLA signal was analysed as overlap coefﬁcient by using
Zen software.
Coimmunoprecipitation assay. Cell lysates from HEK293T cells were collected
and lysed in the triton lysis buffer: 10mM Tris-HCl pH 8.0, 2.5mM MgCl2, 5mM
EGTA pH 8.0, 0.5% Triton X-100 (w/v), 1mM Na3VO4, 50mM NaF and 1 tablet
of protease inhibitor cocktail (Roche) per 10ml of buffer. Anti-Flag M2 magnetic
beads (Sigma) were used to isolate co-immunoprecipitated complex with
Flag-tagged proteins, and Anti-HA matrix (Roche) were used to isolate
co-immunoprecipitated complex with HA-tagged proteins. Beads and matrix
were washed following manufacturer’s instruction.
GST pull-down assay. The GST-tagged NLRP3 (1-219aa) was induced and
expressed as described50. Puriﬁed GST-tagged NLRP3 (1-219 aa) was immobilized
on the glutathione sepharose 4B beads (GE healthcare). Puriﬁed full-length
recombinant MARK4 protein was obtained from MRC-PPU (the University of
Dundee, UK), and applied to those beads. Washing steps were followed as
described50. Samples were then subjected to western blot analysis.
ASC oligomerization assay. Cells were lysed with TBS-triton buffer (50mM
Tris-HCL, pH 7.4, 150mM NaCl, 0.5% Triton X-100) complemented with EDTA-
free protease inhibitor (Roche). The lysates were centrifuged at 6,000 g for 15min at
4 C. The pellets were used as triton-insoluble fraction, and the supernatants were
used as triton-soluble fraction. The triton-insoluble pellets were washed twice with
TBS buffer (50mM Tris-HCL, pH 7.4, 150mM NaCl). The pellets were then
resuspended in 300ml TBS buffer. The resuspended pellets underwent crosslinkage
for 30min at 37 C with 2mM disuccinimidyl suberate (Pierce), and were then
centrifuged and dissolved in LDS sample buffer for western blot.
Western blot. Supernatant of cells stimulated with inﬂammasome activator was
collected in serum-free media. TCA protein precipitation was performed on those
supernatant to detect cleaved IL-1b and caspase-1. Western samples were separated
using precast NuPAGE Novex 4–12% Bis-Tris gels (Invitrogen), and proteins were
transferred onto PVDF Immobilon-FL membrane (Millipore). After antibody
detections, membranes were analysed using Odyssey infrared imaging system
(LICOR) or enhanced chemiluminescence (ECL, GE Healthcare) to reveal the
bands. See supplementary Fig. 17 for gel source data.
Mitochondria fractionation. BMDM cells were primed with 1 mgml 1 of LPS for
4 h, then stimulated with 7.5 mM nigericin for 30min. Subcellular fractions were
obtained using mitochondria isolation kit for cultured cells (Thermo, Cat. NO.
89874), and then subject to western blot. Tom20 was used to reveal mitochondria
fraction, and ERK2 was used to reveal cytoplasm fraction.
ELISA and meso scale discovery. ELISA kits of mouse IL-1b ELISA (559603),
human IL-1b ELISA (557953) were obtained from BD biosciences, and Mouse
TNF ELISA (DY410) was obtained from R&D. ELISA assays were performed
according manufacturer’s instructions. MSD assay of mouse IL-1b was performed
by core biochemical assay laboratory of Cambridge University Hospitals, and the
detection limit of mouse IL-1b by MSD is 3.5 pgml 1.
Flow cytometry. Peritoneal exudate cells were collected by lavage. Cells were
stained with markers CD11b, Ly6G, and Ly6C. Stained cells were subject to
Fortessa Cell Analyser (BD, USA). Ly6Ghi Ly6Cþ cells from CD11b positive cells
were counted as neutrophil. Data were analysed by FlowJo.
Neutrophil migration assay. Mouse neutrophils were isolated from blood using
miltenyi biotec kit (Miltenyi). Isolated neutrophil were then subject to transwell
migration assay, and CXCL12 was used as attractant. The incubation was
performed in 37 C cell culture incubator for 4 h. Migrated cells were then collected
and counted.
Phagocytosis assay. Cells were co-incubated with MSU crystals for 4 h at in 37 C
cell culture incubator. Cells were then thoroughly washed and stained with Cholera
Toxin Subunit B (Invitrogen). Phagocytosed MSU images were taken by reﬂection
confocal microscopy. Fluorescence intensity of phagocytosed MSU was analysed by
reﬂection signals per cell. Analysis was performed using ImageJ. Vybrant phagocy-
tosis assay kit (Invitrogen) was also used following manufacturer’s instructions.
Statistics. Statistical analysis was performed with Prism (Graphpad). All data were
expressed as Mean±s.e.m. Comparisons of the two different groups were analysed
by unpaired t test. Po0.05 (*), Po0.01 (**), Po0.001(***), or Po0.0001(****) was
considered statistically signiﬁcant.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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